Dr. Lambert Busque CML Chronic Myeloid Leukemia
Dr Busque is a practicing hematologist at Hôpital Maisonneuve-Rosemont (HMR), and serves as Chief of Molecular diagnostic and Chief of HMR’s Diagnostic Program of Medical biology being altogether responsible for 300 employees and managing a budget of 30 Million$/year. He sits on several Quebec government regulatory committees such as the Institut National d’Excellence en Santé et Services Sociaux (INESSS). He is the co-founder of the Quebec CML Registry and a founder and current president of the non-for-profit organization GQR-LCM/NMP (Groupe québécois de recherche en leucémie myéloide chronique et en néoplasies myéloprolifératives) where he successfully built a network comprising 20 oncology centers in the province of Quebec. Dr. Busque is a sought after as a key opinion leader (KOL), and his advice and expertise are critical to numerous pharmaceutical companies.
Extract of Your emotions and cancer by Canadian Cancer Society
VIDEO
C3I Press conference Maisonneuve Rosemont Hospital - Dr. Busque
July 12, 2016, Help Save Matthew
C3I Press conference Maisonneuve Rosemont Hospital - Dr. Busque
July 12, 2016, Help Save Matthew
ARTICLES
Under certain conditions, bacterial signals set the stage for leukemia
May 16, 2018, UChicago Medicine
Montréal at the forefront of oncology research and cancer treatment
July 20, 2017, Blog Montreal
Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia
December 2015, ASH 2015
REAL LIFE ANALYSIS OF CML MANAGEMENT DEMONSTRATES THAT SECOND-LINE THERAPY IS FREQUENTLY USED BUT IS PREMATURELY DISCONTINUED FOR INTOLERANCE: REPORT OF THE GROUPE QUÉBÉCOIS DE RECHERCHE EN LMC-NMP
June 13, 2015, EHA 2015
Under certain conditions, bacterial signals set the stage for leukemia
May 16, 2018, UChicago Medicine
Montréal at the forefront of oncology research and cancer treatment
July 20, 2017, Blog Montreal
Comparative Effectiveness of Generic Imatinib and Brand-Name Imatinib for the Treatment of Chronic Myeloid Leukemia
December 2015, ASH 2015
REAL LIFE ANALYSIS OF CML MANAGEMENT DEMONSTRATES THAT SECOND-LINE THERAPY IS FREQUENTLY USED BUT IS PREMATURELY DISCONTINUED FOR INTOLERANCE: REPORT OF THE GROUPE QUÉBÉCOIS DE RECHERCHE EN LMC-NMP
June 13, 2015, EHA 2015